CoChat

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Impact on carnitine homeostasis of short-term treatment with the pivalate prodrug cefditoren pivoxil

Brass, E · 2003 · Clinical Pharmacology & Therapeutics

Abstract

BACKGROUND: Pivalate-generating prodrugs have been suggested to cause clinically significant hypocarnitinemia. To evaluate the effect of pivalate prodrug treatment on carnitine homeostasis, we administered a pivalate prodrug, cefditoren pivoxil, to healthy subjects and performed carnitine balance studies. METHODS: Cefditoren pivoxil was administered in one of two dosing regimens (200 mg cefditoren twice daily for 10 days or 400 mg cefditoren twice daily for 14 days) to gender-balanced groups of 15 subjects. Plasma and urine concentrations of carnitine, acetylcarnitine, pivaloylcarnitine, and total carnitine were quantified before, during, and after treatment. RESULTS: Plasma carnitine concentrations fell during cefditoren pivoxil dosing. The nadir in carnitine concentration was dependent on the dose of cefditoren and subject gender (decrease from 44.8 +/- 10.9 micromol/L to 9.2 +/- 1.9 micromol/L in male patients and from 32.5 +/- 5.4 micromol/L to 6.3 +/- 1.7 micromol/L in female patients after 14 days of 400 mg cefditoren twice daily). Urinary elimination of pivaloylcarnitine resulted in a marked increase in total carnitine excretion, as well as net losses of total carnitine of approximately 4.6 mmol with the 200-mg, 10-day regimen and up to 14.9 mmol with the 400-mg, 14-day regimen. Pivaloylcarnitine was the dominant form of excreted pivalate. DISCUSSION: Short-term administration of cefditoren pivoxil results in hypocarnitinemia and increased net losses of total carnitine. It is estimated that net carnitine losses were only 10% of body stores, even with the highest dose regimen tested. Losses of this magnitude would not be anticipated to result in adverse clinical effects.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0009-9236(02)17636-3

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 36 references

Cited by

See all 50

Metadata

Authors
Brass, E.
Affiliations
University of California, Los Angeles (US)
Corresponding author
Brass, E
Venue
Clinical Pharmacology & Therapeutics
Publisher
Wiley
Published
2003-04
Volume
73
Issue
4
Pages
338-347
ISSN
0009-9236 (ISSN-L)
OpenAlex
W2006024908
Cited by
50
References
36
Citations by year
2026: 1 · 2025: 3 · 2023: 1 · 2022: 1 · 2021: 3 · 2020: 1 · 2019: 1 · 2017: 1 · 2016: 2 · 2015: 5 · 2013: 3 · 2012: 2
FWCI
2.36
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Pharmacology & Therapeutics (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
Keywords
cefditoren pivoxil, carnitine homeostasis, urinary carnitine excretion, acetyl-L-carnitine, plasma carnitine, dose-dependent effects, sex differences, cephalosporin adverse effects
MeSH terms
Adult, Carnitine, Cephalosporins, Chromatography, High Pressure Liquid, Drug Administration Schedule, Female, Homeostasis, Humans, Male, Gas Chromatography-Mass Spectrometry, Metabolic Clearance Rate, Middle Aged, Prodrugs

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Impact on carnitine homeostasis of short-term treatment with the pivalate prodrug cefditoren pivoxil. https://app.cochat.ai/papers/10.1016/s0009-9236(02)17636-3
The paper
Brass, E. (2003). Impact on carnitine homeostasis of short-term treatment with the pivalate prodrug cefditoren pivoxil. Clinical Pharmacology & Therapeutics. https://doi.org/10.1016/s0009-9236(02)17636-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.